Levo Therapeutics
Advancing genetic science for breakthrough treatments in severe neurodevelopmental disorders
Advancing genetic science for breakthrough treatments in severe neurodevelopmental disorders
Levo Therapeutics, founded in 2016, is a biomedical research and development company striving to revolutionize treatments for severe neurodevelopmental disorders. Their slogan, "Advancing genetic science for breakthrough treatments in severe neurodevelopmental disorders," underscores their commitment to leveraging genetic insights. The company focuses on treating multisystem neurodevelopmental disorders, particularly Prader-Willi syndrome and related conditions. In November 2019, Levo Therapeutics secured a significant $40.00M Venture Round investment to further their mission. The investors behind this pivotal funding round were not disclosed. As a player in the Biotechnology and Pharmaceutical industries, Levo Therapeutics is dedicated to empowering patients to overcome severe neurodevelopmental challenges through innovative genetic science.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $40.00M | - | 22 Nov 2019 | |
| Series A | Unknown | 1 |
|
11 Aug 2017 |
No recent news or press coverage available for Levo Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
